One of 5 listed pharmas spending more than 10% of their sales into R&D
Listed pharmaceutical companies have been criticized to pay no attention in making investment into R&D.
Yakup Shinmoon(www.yakup.com) analyzed KOSPI and KOSDAQ listed pharmaceutical companies’ 2018 first half business report, and the analysis result showed that they had an 8.04% R&D investment r...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
